Fusen Pharmaceutical Company Limited

SEHK:1652 Voorraadrapport

Marktkapitalisatie: HK$739.3m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Fusen Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

De CEO Fusen Pharmaceutical's is Dudu Cao, benoemd in Jan2013, heeft een ambtstermijn van 11.75 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 5.00M, bestaande uit 32.4% salaris en 67.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 20.92% van de aandelen van het bedrijf, ter waarde HK$ 148.46M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.5 jaar en 7.5 jaar.

Belangrijke informatie

Dudu Cao

Algemeen directeur

CN¥5.0m

Totale compensatie

Percentage CEO-salaris32.4%
Dienstverband CEO11.8yrs
Eigendom CEO20.9%
Management gemiddelde ambtstermijn5.5yrs
Gemiddelde ambtstermijn bestuur7.5yrs

Recente managementupdates

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

May 21
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31
Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Dec 14
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Sep 02
Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Apr 02
Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

Mar 06
A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08
We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28
Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07
What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20
If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Analyse CEO-vergoeding

Hoe is Dudu Cao's beloning veranderd ten opzichte van Fusen Pharmaceutical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-CN¥90m

Mar 31 2024n/an/a

-CN¥63m

Dec 31 2023CN¥5mCN¥2m

-CN¥36m

Sep 30 2023n/an/a

-CN¥24m

Jun 30 2023n/an/a

-CN¥11m

Mar 31 2023n/an/a

-CN¥23m

Dec 31 2022CN¥2mCN¥2m

-CN¥35m

Sep 30 2022n/an/a

-CN¥34m

Jun 30 2022n/an/a

-CN¥34m

Mar 31 2022n/an/a

-CN¥9m

Dec 31 2021CN¥2mCN¥2m

CN¥17m

Sep 30 2021n/an/a

CN¥48m

Jun 30 2021n/an/a

CN¥79m

Mar 31 2021n/an/a

CN¥75m

Dec 31 2020CN¥2mCN¥1m

CN¥70m

Sep 30 2020n/an/a

CN¥67m

Jun 30 2020n/an/a

CN¥65m

Mar 31 2020n/an/a

CN¥59m

Dec 31 2019CN¥548kCN¥516k

CN¥53m

Sep 30 2019n/an/a

CN¥63m

Jun 30 2019n/an/a

CN¥72m

Mar 31 2019n/an/a

CN¥87m

Dec 31 2018CN¥251kCN¥242k

CN¥102m

Compensatie versus markt: De totale vergoeding ($USD 711.96K ) Dudu } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 233.84K ).

Compensatie versus inkomsten: De vergoeding van Dudu is gestegen terwijl het bedrijf verliesgevend is.

CEO

Dudu Cao (38 yo)

11.8yrs

Tenure

CN¥4,997,000

Compensatie

Mr. Zhiming Cao, also known as Dudu Cao is the Executive Director and Chief Executive Officer of Fusen Pharmaceutical Company Limited since January 18, 2013, who is primarily responsible for the general ma...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Changcheng Cao
Executive Chairman7.9yrsCN¥65.00k27.93%
CN¥ 206.5m
Zhiming Cao
CEO & Executive Director11.8yrsCN¥5.00m20.92%
CN¥ 154.7m
Taisheng Hou
Executive Directorno dataCN¥81.00kgeen gegevens
Yongsheng Chi
Executive Directorno dataCN¥78.00kgeen gegevens
Qingfen Meng
Executive Directorno dataCN¥62.00kgeen gegevens
Zhen Li
Chief Financial Officer5.5yrsgeen gegevensgeen gegevens
Tik Man Wong
Company Secretary3.8yrsgeen gegevensgeen gegevens

5.5yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1652 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Changcheng Cao
Executive Chairman7.9yrsCN¥65.00k27.93%
CN¥ 206.5m
Zhiming Cao
CEO & Executive Director11.8yrsCN¥5.00m20.92%
CN¥ 154.7m
Taisheng Hou
Executive Director7.5yrsCN¥81.00kgeen gegevens
Yongsheng Chi
Executive Director7.5yrsCN¥78.00kgeen gegevens
Qingfen Meng
Executive Director7.5yrsCN¥62.00kgeen gegevens
Kwok Tung Lee
Independent Non-Executive Director5.5yrsCN¥162.00kgeen gegevens
Wing Chun Sze
Independent Non-Executive Director6.3yrsCN¥162.00kgeen gegevens
Kit Wa To
Independent Non-Executive Director4.2yrsCN¥162.00kgeen gegevens

7.5yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1652 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.5 jaar).